BRPI0607238A2 - anticorpos anti-interferon gama humanos e métodos de seu uso - Google Patents

anticorpos anti-interferon gama humanos e métodos de seu uso

Info

Publication number
BRPI0607238A2
BRPI0607238A2 BRPI0607238-0A BRPI0607238A BRPI0607238A2 BR PI0607238 A2 BRPI0607238 A2 BR PI0607238A2 BR PI0607238 A BRPI0607238 A BR PI0607238A BR PI0607238 A2 BRPI0607238 A2 BR PI0607238A2
Authority
BR
Brazil
Prior art keywords
methods
antibodies
interferon gamma
ifnγ
human anti
Prior art date
Application number
BRPI0607238-0A
Other languages
English (en)
Inventor
Walter Ferlin
Nicolas Fischer
Greg Elson
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of BRPI0607238A2 publication Critical patent/BRPI0607238A2/pt
Publication of BRPI0607238B1 publication Critical patent/BRPI0607238B1/pt
Publication of BRPI0607238B8 publication Critical patent/BRPI0607238B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ANTICORPOS ANTI-INTERFERON GAMA HUMANOS E MéTODOS DE SEU USO. A invenção se refere a anticorpos totalmente humanos e seus fragmentos, que se ligam a interferon gama humano (hIFNy) , modulando assim a interação entre IFNy e seu receptor IFNy-R, e/ou modulando as atividades biológicas de IFNy. A invenção também se refere ao uso de tais anticorpos antiIFNy na prevenção ou tratamento de distúrbios imunorelacionados e na melhora de um sintoma associado com um distúrbio imuno-relacionado.
BRPI0607238A 2005-01-27 2006-01-27 anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas BRPI0607238B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64821905P 2005-01-27 2005-01-27
US60/648.219 2005-01-27
PCT/IB2006/001514 WO2006109191A2 (en) 2005-01-27 2006-01-27 Human anti-interferon gamma antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
BRPI0607238A2 true BRPI0607238A2 (pt) 2009-08-25
BRPI0607238B1 BRPI0607238B1 (pt) 2019-10-15
BRPI0607238B8 BRPI0607238B8 (pt) 2021-05-25

Family

ID=37087400

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607238A BRPI0607238B8 (pt) 2005-01-27 2006-01-27 anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas

Country Status (20)

Country Link
US (4) US7700098B2 (pt)
EP (1) EP1848744B1 (pt)
JP (1) JP5173437B2 (pt)
KR (1) KR101380570B1 (pt)
CN (1) CN101151277B (pt)
AT (1) ATE541859T1 (pt)
AU (1) AU2006233353B2 (pt)
BR (1) BRPI0607238B8 (pt)
CA (1) CA2595276C (pt)
DK (1) DK1848744T3 (pt)
EA (1) EA013118B1 (pt)
ES (1) ES2381203T3 (pt)
IL (1) IL184749A0 (pt)
MX (1) MX2007008719A (pt)
NO (1) NO340445B1 (pt)
PL (1) PL1848744T3 (pt)
PT (1) PT1848744E (pt)
UA (1) UA92337C2 (pt)
WO (1) WO2006109191A2 (pt)
ZA (1) ZA200706169B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0820073A2 (pt) * 2007-11-12 2015-06-23 U3 Pharma Gmbh Anticorpos anti-axl
DE602008004898D1 (de) * 2008-06-27 2011-03-24 Theranor Sprl Pharmazeutische Zusammensetzungen von Antikörpern von Viruserkrankungen
US20100093087A1 (en) 2008-10-07 2010-04-15 Novlmmune S.A. IL-17 Mediated Transfection Methods
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
SG11201402490XA (en) * 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2018515493A (ja) 2015-05-07 2018-06-14 ノビミューン エスアー Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
CN105695405A (zh) * 2016-03-29 2016-06-22 深圳爱生再生医学科技有限公司 Cik细胞扩增方法
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
BR112019008156A2 (pt) * 2016-10-24 2019-07-02 Novimmune S.A. métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama
TWI797124B (zh) * 2017-05-05 2023-04-01 香港商安立璽榮生醫(香港)有限公司 抗干擾素-γ之抗體及其應用
AU2018321893A1 (en) 2017-08-23 2020-03-19 Wayne State University In vivo immunoimaging of interferon-gamma
WO2019108456A1 (en) 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
KR20200138167A (ko) * 2018-03-29 2020-12-09 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 Hbv 감염 치료 방법
EP3853377A4 (en) * 2018-09-19 2022-10-05 Totient, Inc. ANTIBODY COMPOSITIONS ASSOCIATED WITH CANCER AND METHODS OF USE
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
WO2022132710A1 (en) * 2020-12-15 2022-06-23 Vanderbilt University Human hendra virus and nipah virus antibodies and methods of use therefor
TW202241964A (zh) 2021-01-08 2022-11-01 美商必治妥美雅史谷比公司 因子xia抑制劑之抗體及抗原結合肽及其用途
CN112794903B (zh) * 2021-04-14 2021-06-25 广州市雷德生物科技有限公司 一种特异性结合IFN-γ的抗体及其应用
JP7359457B2 (ja) * 2021-10-11 2023-10-11 タグシクス・バイオ株式会社 自己免疫性疾患治療薬
EP4531919A4 (en) * 2022-06-02 2026-06-24 Elixiron Immunotherapeutics Hong Kong Ltd Interferon-gamma antibody treatment for vitiligo
JP2024021165A (ja) * 2022-08-03 2024-02-16 タグシクス・バイオ株式会社 ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
JP2024021164A (ja) * 2022-08-03 2024-02-16 タグシクス・バイオ株式会社 ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬
EP4724095A1 (en) 2023-06-09 2026-04-15 Children's Hospital Medical Center Treatment of stem cell graft failure
WO2025024431A1 (en) * 2023-07-24 2025-01-30 Vanderbilt University Broadly reactive antibodies to influenza b viruses
EP4750803A1 (en) * 2023-07-25 2026-06-03 Cymab ApS Antigen-binding molecules capable of binding interferon gamma
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
US20250334587A1 (en) 2024-04-26 2025-10-30 Swedish Orphan Biovitrum Ag Use of emapalumab for treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2148907C (en) 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003097082A2 (en) * 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
CN102215522A (zh) 2002-06-27 2011-10-12 美商内数位科技公司 宽频码分多址第一无线网络控制器
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis

Also Published As

Publication number Publication date
EA013118B1 (ru) 2010-02-26
NO20073882L (no) 2007-10-24
US9682142B2 (en) 2017-06-20
IL184749A0 (en) 2007-12-03
UA92337C2 (uk) 2010-10-25
KR101380570B1 (ko) 2014-04-01
US7700098B2 (en) 2010-04-20
US20060263363A1 (en) 2006-11-23
CN101151277B (zh) 2013-11-13
NO340445B1 (no) 2017-04-24
CA2595276A1 (en) 2006-10-19
EP1848744A2 (en) 2007-10-31
KR20070102566A (ko) 2007-10-18
CN101151277A (zh) 2008-03-26
US20100158922A1 (en) 2010-06-24
JP5173437B2 (ja) 2013-04-03
US20140186362A1 (en) 2014-07-03
US20170291943A1 (en) 2017-10-12
WO2006109191A3 (en) 2007-04-26
WO2006109191A2 (en) 2006-10-19
CA2595276C (en) 2014-03-11
DK1848744T3 (da) 2012-03-19
ZA200706169B (en) 2008-04-30
MX2007008719A (es) 2007-09-11
ES2381203T3 (es) 2012-05-24
JP2008528569A (ja) 2008-07-31
BRPI0607238B8 (pt) 2021-05-25
HK1110601A1 (en) 2008-07-18
EA200701589A1 (ru) 2008-02-28
PL1848744T3 (pl) 2012-06-29
ATE541859T1 (de) 2012-02-15
PT1848744E (pt) 2012-04-24
AU2006233353B2 (en) 2011-12-15
AU2006233353A1 (en) 2006-10-19
BRPI0607238B1 (pt) 2019-10-15
EP1848744B1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
BRPI0607238B8 (pt) anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
BRPI0511616A (pt) compostos
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
MY163032A (en) Human anti-il-23 antibodies, compositions, methods and uses
DE602004030341D1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
WO2008106200A3 (en) Human anti-ip-10 antibodies and uses thereof
AR043616A1 (es) Anticuerpos contra receptor humano il-21 y usos de los mismos
BR112022013756A2 (pt) Anticorpos anti-trem2 e métodos de uso dos mesmos
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DE60224291D1 (de) System zur antikörperexpression und- synthese
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
DE60026691D1 (de) Staphylococcus-antigene und impstoff
BR0214250A (pt) peptìdeos que promovem a aderência, crescimento e secreção da célula
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
ATE98130T1 (de) Kombination von angiotensin-converting-enzymehemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: NOVIMMUNE S.A. (CH)

B25A Requested transfer of rights approved

Owner name: EMACO SA (CH)

B25A Requested transfer of rights approved

Owner name: SWEDISH ORPHAN BIOVITRUM AG (CH)